Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002;99:2179–84 .

Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–80.

Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–42.

Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527–43.

Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev Cancer 2002;2:795–803.

Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002;8:3226–31.

Gerber H-P, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. Mol Med 2003;81:20–31.

Goede V, Schmidt T, Kimmina S, et al. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998;78:1835–94 .

Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843–50.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004;350:2335–42.

Jung Y. Ahmad S, Akagi Y, et al. Role of the tumour microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev 2000;19:147–57.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5 .

Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002;2:727–39.

Li J, Zhang Y-P, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microscopy Res Tech 2003;60:107–14.

Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851–6.

Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–9.

Sledge GW, Jr, Miller KD. Angiogenesis and antiangiogenic cancer. Current Prob Cancer 2002;26:1–60.

Stacker A, Baldwin ME, Achen MG. The role of lymphangiogenesis in metastatic spread. FASEB J 2002;16:922–34.

Tapa de la página